April 5, 2016
The investigational PET contrast agent for myocardial perfusion imaging (MPI), flurpiridaz F 18, was found to be superior to MPI with SPECT for assessing coronary artery disease (CAD) in obese patients. The findings were presented yesterday by Lantheus at the American College of Cardiology’s annual scientific session in Chicago.
“SPECT image quality and accuracy decreases as BMI increases, due to a number of factors including more scatter, more attenuation, and lower counts,” Dr. Timothy Bateman, cardiologist at Mid America Heart Institute and the presenter of the study, told HCB News. “PET instrumentation reduces scatter and corrects for attenuation. PET quality is preserved as BMI increases, especially with F-18 tracers.”